Review
Biochemistry & Molecular Biology
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
Summary: Molecular targeted therapy focusing on the HER-2 signaling pathway in gastric cancer has gained attention, with trastuzumab being the only approved drug for HER-2 positive advanced gastric cancer. Ongoing research is developing novel HER2-targeted drugs, and clinical trials are exploring various approaches to overcome resistance and improve treatment outcomes for HER2-positive gastric cancer patients.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2021)
Article
Biochemistry & Molecular Biology
Diksha A. Varma, Mrityunjay Singh, Sharad Wakode, N. E. Dinesh, Simran Vinaik, Shailendra Asthana, Manisha Tiwari
Summary: This study used structure-based pharmacophore mapping and virtual screening to identify a compound SN00020821 from a natural source that can simultaneously interact with c-MET, EGFR, and VEGFR-2 receptor tyrosine kinases. The compound showed good interaction energies with all three targets and stable key interactions with critical amino acids. It also met the requirements for drug-likeness.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Review
Medicine, General & Internal
Shin Ariga
Summary: Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that is overexpressed in 20% of gastric or gastroesophageal junction cancers. While effective in breast cancer, the use of anti-HER2 agents in gastric cancer has not shown survival benefits compared to standard therapies due to inherent differences in tumor biology. However, the development of a novel anti-HER2 agent, trastuzumab deruxtecan, offers promising future prospects for HER2-targeted therapy in gastric cancer.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
M. Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Aoife Carr, Clare Morgan, Julie Workman, Paul Armstrong, Jennifer McAuley, Stephen Madden, Joanna Fay, Katherine M. Sheehan, Elaine W. Kay, Ciara Holohan, Yasir Elamin, Shereen Rafee, Patrick G. Morris, Oscar Breathnach, Liam Grogan, Bryan T. Hennessy, Sinead Toomey
Summary: Aberrant PI3K signaling is related to trastuzumab resistance in HER2-positive gastric cancer. PIK3CA mutations were only found in HER2-negative tumors, while ERBB-family mutations were identified in both HER2-positive and HER2-negative tumors. Copanlisib showed anti-proliferative effects in 4/5 cell lines, and combination with anti-HER2 therapy significantly improved growth inhibition in HER2-positive GC cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Hongjuan Yao, Wenping Song, Rui Cao, Cheng Ye, Li Zhang, Hebing Chen, Junting Wang, Yuchen Shi, Rui Li, Yi Li, Xiujun Liu, Xiaofei Zhou, Rongguang Shao, Liang Li
Summary: Chemoresistance is a main limitation for the treatment of pancreatic ductal adenocarcinoma (PDAC). Here, the authors show that an antibody drug conjugate-like compound targeting both EGFR and HER2 overcomes gemcitabine resistance in PDAC preclinical models by mechanisms involving the tumour suppressor SMAD4.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Tomohiro Enokida, Makoto Tahara
Summary: Anti-VEGFR therapy is crucial in treating thyroid cancer but can lead to dangerous adverse reactions. To minimize risks, physicians need to understand the characteristics of these reactions and take appropriate measures. The development of multitarget tyrosine kinase inhibitors has improved prognosis, but effective management of related adverse events is essential.
Article
Chemistry, Analytical
Ji Tao, Yuanbiao Tu, Peifei Liu, Yongjia Tang, Fang Wang, Zhaolun Li, Chang Li, Yi Li, Yi Ma, Yueqing Gu
Summary: Colorectal cancer (CRC) is a highly heterogeneous genetic disease and early diagnosis is crucial. Molecular-based fluorescence imaging can effectively enhance cancer detection, and the new Crizotinib-PEG(4)-MPA fluorescence probe has the potential to diagnose colorectal cancer and distinguish colon adenomas.
Article
Oncology
Luis D. Borrero-Garcia, Maria del Mar Maldonado, Julia Medina-Velazquez, Angel L. Troche-Torres, Luis Velazquez, Nilmary Grafals-Ruiz, Suranganie Dharmawardhane
Summary: Despite the availability of targeted therapies for cancers expressing oncogenic EGFR and HER2, resistance to therapy remains a challenge. In a study on breast cancer cells, gefitinib and lapatinib resistant variants exhibited enhanced mesenchymal and cancer stem cell-like characteristics, along with increased expression and activation of the small GTPase Rac, suggesting Rac inhibition as a potential strategy to overcome therapy resistance.
Article
Oncology
Seokhwi Kim, Ji Mi Ahn, Won Jung Bae, Jae Ho Han, Dakeun Lee
Summary: Despite the failure of most clinical trials, a new concept of quantitation of stroma-induced HGF was introduced to assess MET signalling activity in gastric cancer. High doses of HGF or CM fully activated MET signalling cascades, and high stromal proportion denoted worse patient survival in MET-positive GCs. The sensitivity to crizotinib was increased with sufficient ligand-dependent MET signalling activation.
Article
Oncology
Lucia Gandullo-Sanchez, Atanasio Pandiella
Summary: By studying resistant clones derived from HER2+ breast cancer cell line, it was found that resistance to T-DM1 was associated with decreased levels of HER2, but the cells still depended on HER2. Antibody array analysis revealed the expression of EGFR in T-DM1-resistant cells, and targeted therapy against EGFR showed an anti-proliferative effect on these cells.
Article
Cell Biology
Pinar Ozden Eser, Raymond M. Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M. Haikala, Ciric To, Jeffrey J. Okoro, Kshiti H. Dholakia, Jihyun Choi, Yoonji Eum, Atsuko Ogino, Pavlos Missios, Dalia Ercan, Man Xu, Michael J. Poitras, Stephen Wang, Kenneth Ngo, Michael Dills, Masahiko Yanagita, Timothy Lopez, Mika Lin, Jeanelle Tsai, Nicolas Floch, Emily S. Chambers, Jennifer Heng, Rana Anjum, Alison D. Santucci, Kesi Michael, Alwin G. Schuller, Darren Cross, Paul D. Smith, Geoffrey R. Oxnard, David A. Barbie, Lynette M. Sholl, Magda Bahcall, Sangeetha Palakurthi, Prafulla C. Gokhale, Cloud P. Paweletz, George Q. Daley, Pasi A. Janne
Summary: Some EGFR-mutant, MET-amplified lung cancers may develop dependence on MET activation alone, suggesting that these patients could be treated with a single-agent MET TKI instead of the current standard-of-care EGFR and MET inhibitor combination regimens.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Chung Hyo Kang, Yeongrin Kim, Da Yeon Lee, Sang Un Choi, Heung Kyoung Lee, Chi Hoon Park
Summary: Chimeric antigen receptor (CAR) technology has shown promise in cancer treatment, and the development of anti c-Met CAR T cells demonstrated selective killing of c-Met overexpressed gastric cancer cells, offering a potential effective therapy for gastric cancer patients.
Article
Cell Biology
Meghan Grojean, Margaret A. Schwarz, Johann R. Schwarz, Sazzad Hassan, Urs von Holzen, Changhua Zhang, Roderich E. Schwarz, Niranjan Awasthi
Summary: Elevated expression of growth factors and receptors like c-Met and VEGFR in gastric adenocarcinoma suggest them as potential therapeutic targets. Combination therapy with foretinib, a c-Met/VEGFR2 inhibitor, and nanoparticle paclitaxel showed additive effects in inhibiting tumor growth and improving survival in animal models. Suppression of c-Met and VEGFR2 signaling in GAC may enhance the response to nanoparticle paclitaxel, suggesting a promising therapeutic approach for improving patient outcomes.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Hai Zhong, Jiajia He, Jingjing Yu, Xiang Li, Yuxian Mei, Long Hao, Xu Wu
Summary: The Mig6 protein is suggested as a specific pan-HER inhibitor, targeting and suppressing HER family members with broad selectivity but weak or no activity towards other growth factor receptors. The S1 segment effectively binds to all four HER kinases, with the full-length sequence being required for effective binding, while the hs2 peptide retains some affinity with HER kinases and mimics the biological function of Mig6 protein in suppressing HER4 at cellular level.
Article
Oncology
Yu-Ra Choi, Eun Hye Kang, Sunshin Kim, Seog-Yun Park, Ji-Youn Han, Youngjoo Lee
Summary: This study evaluated the efficacy of single MET inhibition in EGFR-mutant and MET-amplified lung cancer and found that it produced a short-lived response. Further research on novel combination therapy schedules is needed to achieve long-lasting efficacy with less toxicity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Lenka N. C. Boyd, Mahsoem Ali, Laura Kam, Jisce R. Puik, Stephanie M. Fraga Rodrigues, Eline S. Zwart, Freek Daams, Barbara M. Zonderhuis, Laura L. Meijer, Tessa Y. S. Le Large, Elisa Giovannetti, Hanneke W. M. van Laarhoven, Geert Kazemier
Summary: This study assessed the diagnostic potential of the ratio of CA19-9 with bilirubin in patients with cancer of the pancreatic head, distal bile duct cancer, and benign diseases of the periampullary region prior to treatment. The findings suggest that the ratio of CA19-9 and bilirubin has higher diagnostic power and could aid in early diagnosis and improved treatment.
Article
Oncology
Sofie P. G. Henckens, Eliza R. C. Hagens, Mark I. van Berge Henegouwen, Sybren L. Meijer, Wietse J. Eshuis, Suzanne S. Gisbertz
Summary: This study investigates the impact of lymph node yield after transthoracic esophagectomy on lymph node metastasis, complications, and survival in patients with esophageal adenocarcinoma. The results demonstrate that a lymph node yield of 31 or higher is associated with an increased number of positive lymph nodes, improved disease-free survival, and overall survival, without increasing morbidity.
Article
Oncology
Astrid E. Slagter, Irene A. Caspers, Nicole C. T. van Grieken, Iris Walraven, Pehr Lind, Elma Meershoek-Klein Kranenbarg, Cecile Grootscholten, Marianne Nordsmark, Johanna W. van Sandick, Karolina Sikorska, Cornelis J. H. van de Velde, Edwin P. M. Jansen, Marcel Verheij, Hanneke W. M. van Laarhoven, Annemieke Cats
Summary: Perioperative chemotherapy is the standard treatment for patients with resectable gastric cancer, and both cisplatin and oxaliplatin are legitimate options. This study compared the effectiveness of cisplatin and oxaliplatin in these patients and found no significant differences in adverse events, treatment compliance, or survival rates. However, oxaliplatin treatment was associated with a higher incidence of diarrhea compared to cisplatin treatment.
Article
Oncology
Markus Moehler, Anica Hoegner, Anna D. Wagner, Radka Obermannova, Maria Alsina, Peter Thuss-Patience, Hanneke van Laarhoven, Elizabeth Smyth
Summary: Immunotherapy has been successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma. Recent approvals of immune checkpoint inhibitors have enriched the therapeutic options and shown positive clinical outcomes in various treatment lines.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Tiuri E. Kroese, Yuko Takahashi, Florian Lordick, Peter S. N. van Rossum, Jelle P. Ruurda, Sjoerd M. Lagarde, Richard van Hillegersberg, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Summary: This population-based cohort study evaluated the treatment and survival outcomes in gastric cancer patients with liver metastases. The study found that liver oligometastatic disease and trastuzumab treatment were associated with better overall survival, while triplet chemotherapy was not significantly different from doublet chemotherapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Health Care Sciences & Services
Naomi C. A. van der Velden, Ellen M. A. Smets, Mariet Hagedoorn, Allison J. Applebaum, Bregje D. Onwuteaka-Philipsen, Hanneke W. M. van Laarhoven, Inge Henselmans
Summary: This study investigates the extent of patient-caregiver discordance in prognostic information preferences and perceptions among advanced cancer patients. The results show that there are discordances in patients' and caregivers' preferences and perceptions regarding the likelihood of cure and mortality risk. Discordant prognostic information preferences and better physical functioning of caregivers are associated with discordant perceptions of one-year mortality risk.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
(2023)
Article
Oncology
Tiuri E. Kroese, Hanneke W. M. van Laarhoven, Sebastian F. Schoppman, Pieter R. A. J. Deseyne, Eric van Cutsem., Karin Haustermans., Philippe. Nafteux, Melissa Thomas, Radka Obermannova, Hanna R. Mortensen, Marianne Nordsmark, Per Pfeiffer, Anneli Elme, Antoine Adenis, Guillaume Piessen, Christiane J. Bruns, Florian Lordick, Ines Gockel, Markus Moehler, Cihan Gani, Theodore Liakakos, John Reynolds, Alessio G. Morganti, Riccardo Rosati, Carlo Castoro, Francesco Cellini, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Jolanda van Dieren, Marieke Vollebergh, Johanna W. van Sandick, Paul Jeene, Christel T. Muijs, Marije Slingerland, Francine E. M. Voncken, Henk Hartgrink, Geert-Jan Creemers, Maurice J. C. van der Sangen, Grard Nieuwenhuijzen, Maaike Berbee, Marcel Verheij, Bas Wijnhoven, Laurens V. Beerepoot, Nadia H. Mohammad, Stella Mook, Jelle P. Ruurda, Piotr Kolodziejczyk, Wojciech P. Polkowski, Lucjan Wyrwicz, Maria Alsina, Manuel Pera, Tania F. Kanonnikoff, Andres Cervantes, Magnus Nilsson, Stefan Monig, Anna D. Wagner, Matthias Guckenberger, Ewen A. Griffiths, Elizabeth Smyth, George B. Hanna, Sheraz Markar, M. Asif Chaudry, Maria A. Hawkins, Edward Cheong, Richard van Hillegersberg, Peter S. N. van Rossum
Summary: This study aimed to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophago-gastric cancer. Through a series of discussions and expert evaluations, a consensus was reached, which can be used for future research in clinical trials.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Naomi Cornelia Anna van der Velden, Paul K. J. Han, Hanneke W. M. van Laarhoven, Filip Y. F. L. de Vos, Lizza E. L. Hendriks, Sjaak A. Burgers, Anne-Marie C. Dingemans, Jan Maarten W. van Haarst, Joyce Dits, Ellen M. A. Smets, Inge Henselmans
Summary: Discordance between physicians' and patients' prognostic perceptions in advanced cancer care threatens informed medical decision-making and end-of-life preparation, yet this phenomenon is poorly understood. This study examines the extent and predictors of physician-patient discordance in prognostic perceptions.
Review
Oncology
Irit Ben-Aharon, Hanneke W. M. van Laarhoven, Elisa Fontana, Radka Obermannova, Magnus Nilsson, Florian Lordick
Summary: Data shows a significant increase in the incidence of colorectal cancer in younger populations, as well as similar trends in gastric, pancreatic, and biliary tract cancers. The majority of these cases are sporadic and not hereditary, suggesting a potential role for behavioral, lifestyle, nutritional, microbial, and environmental factors. This review explores the current understanding and challenges of early-onset gastrointestinal cancer, and emphasizes the need for further research to develop preventive strategies and tailored early detection.
Letter
Oncology
Lenka N. C. Boyd, Mahsoem Ali, Jisce R. Puik, Laura L. Meijer, Tessa Y. S. Le Large, Hanneke W. M. van Laarhoven, Elisa Giovannetti, Geert Kazemier
CLINICAL CANCER RESEARCH
(2023)
Article
Health Care Sciences & Services
Niels W. L. Peeters, Rick A. Vreman, Geert A. Cirkel, Marie Jose Kersten, Hanneke W. M. van Laarhoven, Lonneke Timmers
Summary: This study aimed to gain insight into patient volumes per hospital of patients treated with systemic anticancer treatment in the Netherlands. The results showed that the majority of Dutch hospitals treat small numbers of patients in oncology, indicating a high level of fragmentation. Further exploration and discussion on how to organize care to improve efficiency and quality is needed.
Review
Oncology
Angelica Petrillo, Elizabeth C. Smyth, Hanneke W. M. van Laarhoven
Summary: Gastroesophageal adenocarcinoma is a heterogeneous disease with a poor prognosis. Chemotherapy has been the mainstay of treatment, but immunotherapy has shown promise in improving survival outcomes. This review discusses emerging targets in GEA, such as fibroblast growth factor receptor and Claudin 18.2, as well as novel agents targeting HER2 and angiogenesis. Cellular therapies like CAR-T and SPEAR-T cells are also explored.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Oncology
Joachim Kikomeko, Tim Schutte, Merel J. M. van Velzen, Rianne Seefat, Hanneke W. M. van Laarhoven
Summary: Many cancer patients use alternative and complementary treatments such as short-term fasting (STF) and fasting mimicking diets (FMDs) to improve their anticancer treatment and reduce side effects. Recent studies have shown promising results of dietary interventions in combination with chemotherapy, slowing down tumor growth and reducing side effects. This review summarizes the current evidence on the feasibility and effects of STF and FMDs in cancer patients receiving chemotherapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Marieke Pape, Pauline A. J. Vissers, Willemieke P. M. Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M. M. Oving, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Summary: This retrospective cohort study investigated the treatment and survival of patients with advanced esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma (GEJC), and gastric adenocarcinoma (GAC). Despite differences in clinical characteristics and treatment strategies, the survival of patients with advanced EAC, GEJC, and GAC was similar. Therefore, excluding EAC patients from clinical trials for patients with molecularly similar GEJC/GAC should be reconsidered.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Simone Augustinus, Hanneke W. M. van Laarhoven, Geert A. Cirkel, Jan Willem B. de Groot, Bas Groot Koerkamp, Teresa Macarulla, Davide Melisi, Eileen M. O'Reilly, Hjalmar C. van Santvoort, Tara M. Mackay, Marc G. Besselink, Johanna W. Wilmink
Summary: The use of imaging is increasing, leading to an increase in the number of asymptomatic patients diagnosed with metastatic pancreatic cancer (mPDAC). Most medical oncologists prefer immediate chemotherapy initiation following diagnosis, but delayed treatment is considered in specific clinical contexts.
Review
Oncology
Rui Wang, Aashiq Hussain, Quanquan Guo, Meimei Ma
Summary: DNA is highly immunogenic and can activate the cGAS-STING pathway, which plays a crucial role in the pathogenesis and progression of neoplastic diseases. The modulation of cGAS-STING signaling holds great promise for cancer therapy, although there are disagreements on whether to activate or inhibit this pathway.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Ali Zarezadeh Mehrabadi, Faezeh Shahba, Hossein Khorramdelazad, Nazanin Aghamohammadi, Milad Karimi, Kowsar Bagherzadeh, Majid Khoshmirsafa, Ramin Massoumi, Reza Falak
Summary: IL-1 receptor accessory protein (IL-1RAP) plays a crucial role in inflammatory conditions and tumorigenesis in the tumor microenvironment. It is involved in the progression, metastasis, and angiogenesis of solid tumors and hematological malignancies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Xiao Tang, Yujie Niu, Jinli Jian, Yuancheng Guo, Yin Wang, Yu Zhu, Bei Liu
Summary: Ferroptosis is an iron-dependent form of cell death that promotes tumor cell death by causing cell membrane rupture and accumulation of lipid peroxides. Extensive research has been conducted to explore the mechanism of ferroptosis inducers, but its role in hematological tumors is still limited.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Tanwei Yuan, Dominic Edelmann, Jakob N. Kather, Ziwen Fan, Katrin E. Tagscherer, Wilfried Roth, Melanie Bewerunge-Hudler, Alexander Brobeil, Matthias Kloor, Hendrik Blaeker, Barbara Burwinkel, Hermann Brenner, Michael Hoffmeister
Summary: The study aimed to analyze and validate previously published CpG-methylation-based prognostic biomarkers and prediction models for colorectal cancer (CRC) prognosis. The results showed that the discrimination ability of the models was insufficient and lacked clinical relevance.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
Review
Oncology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Summary: This article provides a comprehensive overview of therapeutic cancer vaccines, including their classification, clinical application, efficacy, and combination strategies with other therapies. It offers a valuable theoretical basis for the future clinical application and development of therapeutic cancer vaccines.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2024)
